Stocktoria
Lantheus Holdings, Inc. LNTH
Lantheus Holdings, Inc. (LNTH) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $1.5B at a 15.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.26 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-29 | Citizens | Market Outperform (reit) |
| 2026-05-27 | Mizuho | Outperform (main) |
| 2026-05-11 | Truist Securities | Buy (reit) |
| 2026-05-08 | Citizens | Market Outperform (main) |
| 2026-05-08 | Mizuho | Outperform (main) |
| 2026-04-15 | Truist Securities | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.254 |
| Retained earnings / assets | 0.305 |
| EBIT / assets | 0.14 |
| Equity / liabilities | 0.958 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LNTH | Lantheus Holdings, Inc. | 4/9 | 4.61 | 30.6 | +0.5% |
| NEOG | NEOGEN CORP | 4/9 | -0.23 | — | -2.7% |
| MYGN | MYRIAD GENETICS INC | 5/9 | -5.88 | — | -1.6% |
| QDEL | QuidelOrtho Corp | 5/9 | -0.56 | — | -1.9% |
| NTLA | Intellia Therapeutics, Inc. | 2/9 | -6.12 | — | +16.9% |
| TKNO | Alpha Teknova, Inc. | 5/9 | -1.59 | — | +7.4% |
| ICCC | IMMUCELL CORP /DE/ | 6/9 | 2.93 | — | +4.3% |
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
FAQ
Is LNTH financially healthy?
Lantheus Holdings, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does LNTH pay a dividend?
No, Lantheus Holdings, Inc. does not currently pay a dividend.
How profitable is LNTH?
In FY2025, Lantheus Holdings, Inc. had a net margin of 15.2% and a return on equity of 21.4%.
Is LNTH overvalued or undervalued?
Lantheus Holdings, Inc. trades at about 29.5× trailing earnings — above its 10-year norm (10-year range 7.3×–143.8×, median 19.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for LNTH?
The average Wall-Street price target for Lantheus Holdings, Inc. is $105.23, about 4.5% above the recent price, from 13 analysts (consensus: strong buy).
Is LNTH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Lantheus Holdings, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a P/E of about 30.6×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.